0000891293-22-000034.txt : 20220706
0000891293-22-000034.hdr.sgml : 20220706
20220706171943
ACCESSION NUMBER: 0000891293-22-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220630
FILED AS OF DATE: 20220706
DATE AS OF CHANGE: 20220706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Craig Adam R
CENTRAL INDEX KEY: 0001339498
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 221069737
MAIL ADDRESS:
STREET 1: C/O INNOVIVE PHARMACEUTICALS, INC.
STREET 2: 555 MADISON AVENUE, 25TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2022-06-30
0
0000891293
CTI BIOPHARMA CORP
CTIC
0001339498
Craig Adam R
3101 WESTERN AVENUE
SUITE 800
SEATTLE
WA
98121
1
1
0
0
President and CEO
common stock
2022-06-30
4
A
0
6183
2.1165
A
22861
D
common stock
2022-07-01
4
M
0
27000
0.8411
A
49861
D
common stock
2022-07-01
4
S
0
27000
6
D
22861
D
common stock
2022-07-05
4
M
0
27000
0.8411
A
49861
D
common stock
2022-07-05
4
S
0
27000
6
D
22861
D
common stock
2022-07-06
4
M
0
18223
0.8411
A
41084
D
common stock
2022-07-06
4
S
0
18223
6.11
D
22861
D
Non-Qualified Stock Option (right to buy)
0.8411
2022-07-01
4
M
0
27000
0
D
2029-05-16
Common Stock
27000
1200777
D
Non-Qualified Stock Option (right to buy)
0.8411
2022-07-05
4
M
0
27000
0
D
2029-05-16
Common Stock
27000
1173777
D
Non-Qualified Stock Option (right to buy)
0.8411
2022-07-06
4
M
0
18223
0
D
2029-05-16
Common Stock
18223
1155554
D
Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.
Adam R. Craig
2022-07-06